Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

n. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II. Angiotensin II is a small peptide in the body and part of the so-called renin-angiotensin system (RAS), an important regulator of blood pressure. Angiotensin II causes blood vessels to narrow,
resulting in increased blood pressure. In a phase IIa clinical trial, vaccination with CYT006-AngQb has been shown to reduce blood pressure by induction of antibodies that bind angiotensin II. Thereby, binding of angiotensin II to its receptors and subsequent narrowing of blood vessels should be decreased. The RAS has already been successfully targeted by three major classes of antihypertensive drugs on the market: inhibitors of the angiotensin-converting-enzyme (ACE), antagonists of the angiotensin II type I receptor (ARBs) and renin inhibitors. Like other antihypertensive drugs these also come with the need for daily dosing and fail to provide a solution for improving patient compliance. Treatment with CYT006-AngQb should allow for convenient dosing schedules and smooth control of blood pressure due to a sustained antibody response induced by vaccination.



About Cytos Biotechnology AG
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The Imm
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
(Date:5/4/2015)... , May 4, 2015 MEI Pharma, ... focused on the clinical development of novel therapies ... mitochondria-specific effects of the Company,s investigational drug candidate ... activity when combined with a tyrosine-kinase inhibitor (TKI). ... to be a potent inhibitor of mitochondrial oxidative ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... , FRANKLIN LAKES, N.J. , ... BDX ), a leading global medical technology company, is increasing ... Haiti earthquake relief efforts from the $500,000 ... in market value of critical medical supplies.  This additional commitment will ...
... , Jan. 27 CardioGenics Holdings Inc. (OTC ... the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, ... self-metering cartridge for its POC diagnostic device, the QL Care ... the self-metering cartridge. , Dr. Yahia Gawad , CEO ...
Cached Medicine Technology:BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 2BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 3CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 2CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 3
(Date:5/4/2015)... 2015 “ Food Cost Calculator ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... to manage and efficiently calculate food costs. , The restaurant ... fact, the industry has an estimated 1.8 trillion dollar impact ...
(Date:5/4/2015)... 2015 The Accreditation for ... first-ever congenital heart disease (CHD) standards for ... accreditation. Driven by the latest available clinical ... review of interventional procedures in pediatric patients ... “The ACE CHD Standards for PCCL Accreditation, ...
(Date:5/4/2015)... “St. Louis has long represented opportunity ... West,” so it is the perfect place for Zerorez ... Ben Litalien, Chief Development Officer for Zerorez. “We ... will provide veterans with a $10,000 discount on our ... have a number of Military Veterans in its ranks ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... Barbara Crone has joined Women’s Excellence in ... of the men, women and families who seek her care, initially ... for families in the home. , “When the ... if I could complete their care with the delivery of their ... mentor Nurse Midwife, I knew it was time for me to ...
Breaking Medicine News(10 mins):Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2
... out on the best drug treatment for their disease, because ... of print in the Archives of Disease in Childhood. ... and the disease prompts up to a third of children ... , The researchers used national data to calculate the number ...
... CINCINNATI, Sept. 3 Most children in the ... Attention Deficit,Hyperactivity Disorder (ADHD) have not been diagnosed ... medications, according to the first,national ADHD prevalence study ... criteria, according to a new study conducted by ...
... appears to be associated with adolescents risk of becoming ... in their lifetimes, according to a report in the ... one of the JAMA/Archives journals. , Previous studies have ... risk of starting to smoke, according to background information ...
... the medications they need, researchers say , , MONDAY, Sept. ... children have attention-deficit/hyperactivity disorder (ADHD), but only 32 percent ... That,s the sobering conclusion of a landmark new study, ... consider the "gold standard" of diagnostic criteria -- the ...
... Stent is Featured at ... ESC Congress 2007, ... from patient subsets of a global registry support,the use of the ... Presented today by Robbert de Winter, M.D., Ph.D., at the European,Society ...
... Cam in Cambridge, famous as a haunt of students ... become the next generation of antibiotics, according to scientists ... for General Microbiologys 161st Meeting at the University of ... With antibiotics now over-prescribed for treatments of bacterial infections, ...
Cached Medicine News:Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 2Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 3Health News:Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New 'Gold Standard' Study by Cincinnati Children's Researchers 4Health News:Teens who see more smoking in movies may have increased risk of becoming established smokers 2Health News:9% of U.S. Kids Have ADHD 2Health News:9% of U.S. Kids Have ADHD 3Health News:Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
Medicine Products: